Bacteremia Clinical Trial
— VISLISIOfficial title:
Virulence of Staphylococcus Lugdunensis in Severe Infections
Verified date | March 2016 |
Source | University Hospital, Strasbourg, France |
Contact | n/a |
Is FDA regulated | No |
Health authority | France: Ministry of Health |
Study type | Interventional |
The main objective is to identify new virulence factors produced by Staphylococcus lugdunensis that can be associated with clinical sign of severe infections and identified symptoms. The methodological approach is based on the comparison between the production of toxins by a given S. lugdunensis isolate classified in patients groups according to the infection clinically defined. Each group will be compared to the presence or not of studied virulence factors. Clinical features associated with toxin activity are not known for S. lugdunensis. This comparative approach is based on the hypotheses that drove to the definition of patient groups and their clinical criteria. However, in the absence of the evident correlation between production of toxins and kind of infection, the statistical evaluation will be completed by a multi-varied analysis. This approach has not been choosen first because of the multiple parameters that undergo during infection that may reveal relationships without true correlation. About the number of included patients in each defined group, if one of them does not reach the expected count, we still might extend inclusions to 3-6 months more. The presence of severe infections without usually defined risk is intriguing. For these last patients, we have planned, after their individual consent to achieve an exome sequencing. The obtained data will be compared to available resources for the human genome. By filtering data through usual protocols, we hope to able to focus onto few genes that evoke specific sensitivity to infections, e.g. severe endocarditis due to S. lugdunensis without defined risk.
Status | Completed |
Enrollment | 82 |
Est. completion date | February 2016 |
Est. primary completion date | February 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age 18 or more - Signed informed consent form - Proved infection by Staphylococcus lugdunensis: bacteremia, urine tract infection, endocarditis, bone and joint infections, skin and soft tissue infection, deep infection. Exclusion Criteria: - Age under 18 - Pregnancy or breastfeeding - Contamination by Staphylococcus lugdunensis |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
France | University Hospital | Strasbourg |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Strasbourg, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Presence/absence of virulence factors | Several groups will be compared considering the presence/absence of virulence factors: Bacteriemic VS non bacteriemic, Deep infection VS Skin/mucosal infection, Foreign body infection VS not, Presence of abscess VS not, Sepsis VS no sepsis, Septic embolism VS not, Portal of entry or not The following virulence factors will be searched for: TSST-1, enterotoxins, leukotoxins, epidermolysins, beta-hemolysins, SCIN-CHIPS, Sbi, Efb, SdrE |
Participants will be followed for the duration of hospital stay, an expected average of 1 week | Yes |
Secondary | Clinical characteristics of infections | Characteristics of infection: comorbidities (Charlson score) - history of the disease - clinical, cytological , immunological, inflammatory and organ functions parameters - results of additional tests conducted under their care - response to treatment - morbidity and mortality | Participants will be followed for the duration of hospital stay, an expected average of 1 week | No |
Secondary | Whole human transcriptome analysis for selected patients | Genetic blood samples will be analyzed together after the end of inclusion period (18 months) | No | |
Secondary | Genome sequencing of selected strains of Staphylococcus lugdunensis | Genetic blood samples will be analyzed together after the end of inclusion period (18 months) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03894046 -
Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
|
Phase 3 | |
Active, not recruiting |
NCT03354338 -
Amoxicillin to Prevent Bacteria and Inflammatory Biomarkers After Intensive Periodontal Therapy
|
Phase 2 | |
Withdrawn |
NCT02543957 -
Factors Associated With Increased Risk of Bacteremia and Cholangitis in ERCP With Cholangioscopy
|
||
Completed |
NCT02210169 -
RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates
|
N/A | |
Completed |
NCT01410578 -
The Value of sTREM-1, PCT, and CRP as Markers for the Detection of Sepsis and Bacteremia Among Patients With a FUO
|
N/A | |
Terminated |
NCT00428051 -
Colombia Epidemiologic Surveillance Study
|
N/A | |
Completed |
NCT00609375 -
Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen
|
Phase 4 | |
Completed |
NCT00177736 -
Pharmacodynamic Parameters of Two Different Doses of Cefepime
|
Phase 4 | |
Terminated |
NCT00108433 -
Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections
|
Phase 3 | |
Completed |
NCT00571259 -
Prophylactic Antimicrobial Catheter Lock
|
Phase 4 | |
Completed |
NCT00027248 -
Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections
|
Phase 3 | |
Completed |
NCT05585463 -
Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
|
||
Recruiting |
NCT05950984 -
Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
|
||
Completed |
NCT03148769 -
Spanish Bacteriemia Cohort 2016: Epidemiology, Clinical Management and Prognosis Factors
|
||
Completed |
NCT02536352 -
Effect of Supplementation of Fluoride on Maternal Periodontal Health, Preterm Delivery, and Perinatal Well-Being
|
Early Phase 1 | |
Completed |
NCT02869191 -
Blood Cultures's Profitability in Intensive Care Unit
|
||
Terminated |
NCT01734694 -
Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients
|
Phase 4 | |
Completed |
NCT01179022 -
Incidence of Bacteremia Following Argon Plasma Coagulation in Patients With Endobronchial Lesions
|
N/A | |
Recruiting |
NCT00404625 -
Infections Caused by ESbL-Producing Enterobacteriaceae in Italy
|
N/A | |
Completed |
NCT00398411 -
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
|
Phase 3 |